<DOC>
	<DOCNO>NCT00002108</DOCNO>
	<brief_summary>To make lamivudine ( 3TC ) available patient progressive , symptomatic HIV disease participate control clinical trial refractory unable tolerate therapy . To collect data pertain safety 3TC two dose level . To evaluate effect 3TC marker hepatitis B co-infected patient five ten select site .</brief_summary>
	<brief_title>3TC ( Lamivudine ; GR109714X ) Open-Label Program</brief_title>
	<detailed_description>Patients 12 year old randomize receive one two dose 3TC duration determine patient 's physician termination program . Patients &lt; 12 year receive low dose 3TC . Patients follow monthly . For select site , serum sample collect every 3 month patient identify HBsAg positive . PER 02/28/95 AMENDMENT : Patients enrol prior 3/1/95 may remain assigned monotherapy dose change combination therapy 3TC zidovudine .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Patients must : Have progressive , symptomatic HIV disease . Have mean CD4 count &lt; = 99 cells/mm3 adult &lt; = 300 cells/mm3 child ( original design CD4 count &lt; = 300 cells/mm3 adult child ) . Be unable participate control trial . Be refractory unable tolerate therapy . Be able attend clinic monthly schedule . Have consent parent guardian age consent . NOTE : If pregnant breastfeed woman request enrollment , physician contact Glaxo staff directly discuss case . Practice unsafe sex .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1995</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>